Skip to main content

Lacticaseibacillus rhamnosus Reduces the Pathogenicity of Escherichia coli in Chickens

  • 2021-06-01
  • Frontiers in Microbiology 12
    • Mengjiao Guo
    • Congyue Zhang
    • Chengcheng Zhang
    • Xiaorong Zhang
    • Yantao Wu

Abstract

Lacticaseibacillus rhamnosus is a recognized probiotic that is widely used in scientific research and clinical applications. This study found that the Lacticaseibacillus rhamnosus GG (LGG) strain can reduce the adhesion of Escherichia coli (E. coli) to primary chicken intestinal epithelial cells by 75.7% and inhibit 41.7% of the E. coli that adhere to intestinal epithelial cells. Additionally, LGG showed strong inhibitory ability on the growth of E. coli, Staphylococcus aureus, Salmonella Paratyphi B, and Salmonella Enteritidis in vitro. Furthermore, the influence of LGG on the growth performance, intestinal flora, immunity, and disease resistance of chickens was explored. Chickens fed with LGG exhibited increased average daily weight gain and concentrations of sIgA, IgG, and IgM than did controls. After 21 days of feeding, a diet with LGG increased the diversity of intestinal microbiota and maintained intestinal health. Moreover, LGG promoted immunologic barriers by upregulating cytokines and chemokines via the Toll-like receptor. The major pro-inflammatory factors, including Myd88, _NF-κ_B, Il6, and Il8, were upregulated compared to controls. After being challenged with E. coli, the survival rate of chickens fed with LGG was significantly higher than those in the control group, and decreased numbers of E. coli were detected in the heart and lungs of the LGG group. In summary, oral administration of LGG to chickens could improve growth performance, maintain intestinal homeostasis, and enhance innate immune response and disease resistance.

Keywords: Lacticaseibacillus rhamnosus; adhesion; disease resistance; innate immune response; intestinal microbiota.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lacticaseibacillus rhamnosusImproved Growth PerformanceBeneficial
Large
Lacticaseibacillus rhamnosusImproved Gut Microbiota DiversityBeneficial
Moderate
Lacticaseibacillus rhamnosusImproved Immune ResponseBeneficial
Large
Lacticaseibacillus rhamnosusImproved Survival Rate After E. coli ChallengeBeneficial
Large
Lacticaseibacillus rhamnosusReduced Pathogen GrowthBeneficial
Large
Lacticaseibacillus rhamnosusReduced Pathogenicity of Escherichia coliBeneficial
Large
Lacticaseibacillus rhamnosus R0011Enhanced Disease ResistanceBeneficial
Large
Lacticaseibacillus rhamnosus R0011Improved Average Daily GainBeneficial
Moderate
Lacticaseibacillus rhamnosus R0011Improved Gut Microbiota DiversityBeneficial
Moderate
Lacticaseibacillus rhamnosus R0011Increased Immunoglobulin LevelsBeneficial
Large
Lacticaseibacillus rhamnosus R0011Reduced Adhesion of Escherichia coliBeneficial
Large
Lacticaseibacillus rhamnosus R0011Reduced Potential Pathogenic BacteriaBeneficial
Large

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.